[Tricuspid regurgitation in 2023 : Where are we with the treatment of the forgotten valve?].

Meier, David; Akodad, Mariama; Tzimas, Georgios; Doguet, Fabien; Jelisejevas, Julius; Boone, Robert H; Sathananthan, Janarthanan; Blanke, Philipp; Leipsic, Jonathon A; Muller, Olivier; Webb, John G; Praz, Fabien (2023). [Tricuspid regurgitation in 2023 : Where are we with the treatment of the forgotten valve?]. Revue médicale suisse, 19(817), pp. 477-485. Médecine & Hygiène 10.53738/REVMED.2023.19.817.477

Full text not available from this repository. (Request a copy)

The negative impact of tricuspid regurgitation on prognosis in now well established. It also appears clear that surgical and possibly percutaneous treatment should be performed before reaching a point of no return with advanced heart failure and deterioration of right ventricle function. Percutaneous treatment has been divided into coaptation restoration devices, annuloplasty devices, and ortho- or heterotopic valve replacement. The present article offers a brief review of diagnostic modalities beyond echocardiography, surgical treatment as well as of the multiple recent development in the percutaneous treatment of this frequent condition.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Praz, Fabien Daniel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0025-6749

Publisher:

Médecine & Hygiène

Language:

French

Submitter:

Pubmed Import

Date Deposited:

09 Mar 2023 09:14

Last Modified:

09 Mar 2023 23:27

Publisher DOI:

10.53738/REVMED.2023.19.817.477

PubMed ID:

36883709

URI:

https://boris.unibe.ch/id/eprint/179748

Actions (login required)

Edit item Edit item
Provide Feedback